COPENHAGEN, Feb 9 (Reuters) - Novo Nordisk's Frankfurt-listed shares rose 4.5% on Monday after telehealth firm Hims & Hers reversed its launch of a $49 compounded weight-loss ‌pill over the weekend, following legal threats from ​Novo and the U.S. Food and Drug ‍Administration.

Hims had introduced the pill ⁠on Thursday ⁠last week, based on semaglutide-a key ingredient in ‌Novo's blockbuster drugs Wegovy ​and Ozempic-sparking pushback from the Danish drugmaker and regulatory authorities. On ⁠Saturday, Hims said ‍it would ​stop offering the treatment after holding "constructive conversations with stakeholders."

Novo Nordisk's shares had already ‍rebounded over 5% on Friday after FDA Commissioner Marty Makary signaled a crackdown on unauthorized compounded GLP-1 medications, which have challenged the drugmaker's pricing power ​in ‍the weight-loss and diabetes markets.

Despite the latest gains, Novo remains under considerable ​pressure as it faces competition from Eli Lilly ( LLY ) and cheaper compounded alternatives. Novo flagged "unprecedented price pressure" at its full-year earnings last week, triggering a 17% stock plunge.

Novo Nordisk's market ​value peaked in June 2024 but it has since shed nearly two-thirds of its value.